ClinicalTrials.Veeva

Menu

Individualized Fortification of Breast Milk (IFO)

M

McMaster Children's Hospital

Status

Unknown

Conditions

Postnatal Growth Disorder
Neurodevelopment

Treatments

Dietary Supplement: Individualized fortification of breast milk
Dietary Supplement: Routine fortification of breast milk

Study type

Interventional

Funder types

Other

Identifiers

NCT01609894
201205IFO

Details and patient eligibility

About

The proposed research will investigate individualized fortification of breast milk based on daily milk analysis of carbohydrate, protein, and fat content in a randomized double blind controlled trial. The combination of additional fat, carbohydrate and protein and commercial fortifier will be added to ensure that the milk contains the target amounts of nutrient. Growth and development of these infants will be compared with that of infants fed mother's milk that has been supplemented with the current standard amounts. The postnatal growth of the infants will be assessed by measuring weight, length and head circumference and fat and lean mass using highly accurate, non-invasive methods throughout the intervention period and at the first follow-up visit after discharge at 3 months. Neurological development will be analyzed at the age of 18 months.

The investigators hypothesize that individualized fortification of breast milk improves the nutritional intake of preterm infants, optimizing growth, and thus this will positively impact neurodevelopment and health.

Enrollment

112 estimated patients

Sex

All

Ages

Under 32 weeks old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Gestational age < 32weeks (maternal dates or early fetal ultrasound);
  2. Tolerating an enteral intake of ≥ 100 ml/kg/d for ≥ 24h;
  3. Subject is anticipated to receive the intervention for ≥ 3 consecutive weeks after full enteral feeding (≥ 150 mL/kg/d) has been achieved; and
  4. Written informed consent has been obtained from the infant's legal representative.

Exclusion criteria

  1. Infants with intrauterine growth restriction, small for gestational age defined by a weight less than 3rd percentile using sex specific reference data for birth weight
  2. Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities;
  3. Babies with enterostoma or short gut syndrome;
  4. Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3);
  5. Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen 10 mmol/L79 and creatinine of 130 mmol/L80;
  6. Hepatic dysfunction, defined by jaundice (direct bilirubin >1.0 mg/dl) that is associated with one or more abnormal liver function tests (AST, ALT or GGT);
  7. Participation in another clinical trial that may affect outcomes of this study; or
  8. Probability of transfer to another NICU or level II nursery outside the McMaster Children's Hospital before the minimum period of three weeks is completed.

Post-randomisation exclusion criteria:

  1. Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk;
  2. Fluid restriction < 140mL/kg/d for ≥ 3 consecutive days;
  3. Sepsis - all infants with gram-negative sepsis will be removed from the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

112 participants in 2 patient groups

Individualized fortification of breast milk
Experimental group
Description:
1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding. 2. Routine fortifier will be added to breast milk batches. 3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level.
Treatment:
Dietary Supplement: Individualized fortification of breast milk
Routine fortification of breast milk
Active Comparator group
Description:
1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding. 2. Routine fortifier will be added to breast milk batches.
Treatment:
Dietary Supplement: Routine fortification of breast milk

Trial contacts and locations

1

Loading...

Central trial contact

Christoph Fusch, MD, PhD, FRCPC; Niels Rochow, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems